The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-26 and is reviewed periodically as new material appears.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
As a potential weapon material, pure uranium-233 is more similar to plutonium-239 than uranium-235 in terms of source (bred vs natural), half-life and critical mass (both 4–5 kg in beryllium-reflected sphere). Unlike reactor-bred plutonium, it has a very low spontaneous fission rate, which combined with its low critical mass made it initially attractive for compact gun-type weapons, such as small-diameter artillery shells. A declassified 1966 memo from the US nuclear program stated that uranium-233 has been shown to be highly satisfactory as a weapons material, though it was only superior to plutonium in rare circumstances. It was claimed that if the existing weapons were based on uranium-233 instead of plutonium-239, Livermore would not be interested in switching to plutonium. The co-presence of uranium-232 can complicate the manufacture and use of uranium-233, though the Livermore memo indicates a likelihood that this complication can be worked around. Chuck Hansen wrote in Swords of Armageddon that 233U was evaluated by the United States for its ability to substitute for supergrade plutonium in nuclear weapons. As it was deemed equivalent to plutonium rather than superior to it, military interest in 233U-based weapons waned in the late 1960s. However, several 233U-based nuclear weapons were tested by the US between 1955 and 1968. The Rocky Flats Plant, which refined fissile materials for weapons production, was refining 233U until the early 1980s.
==== Military ==== The war exposed shortages in the US' weapons stockpiles, calling into question years of defense investment after the September 11 attacks. After less than five months of the war, US was already running out of ammunition against a middle-tier adversary. This could limit US ability to deter other adversaries, including Russia and China. Former secretary of defense Leon Panetta described this as a "dangerous moment". The US has no longer the capacity to deter a future conflict in the South China Sea and elsewhere. The United States consumed more than half of its Patriot missiles used to intercept Iranian missiles and drones. The stockpiles limitation has reportedly turned into a key determinant for continuation or expansion of the conflict. As of 5 August 2026, the US had reportedly used roughly 80% of its THAAD missiles in the war. The United States burned through "virtually all" of its PrSM and ATACMS munitions, and "a little less than half" of its global Tomahawk supply, according to a Reuters report on 4 August. On 6 August, Trump and Hegseth clashed at Camp David over "extreme missile shortages", according to Washington Post. Trump claimed he felt misled, while Hegseth put the blame on his deputy, Stephen Feinberg. Trump denied the aforementioned report, and threatened long prison sentences for anyone leaking information about military supplies. As of 14 August, the US had reportedly lost around 25% of their Reaper drones in the war.
=== Early history === The origins of algorithmically generated media can be traced to the development of the Markov chain, which has been used to model natural language since the early 20th century. Russian mathematician Andrey Markov introduced the concept in 1906, including an analysis of vowel and consonant patterns in Eugene Onegin. Once trained on a text corpus, a Markov chain can generate probabilistic text. By the early 1970s, artists began using computers to extend generative techniques beyond Markov models. Harold Cohen developed and exhibited works produced by AARON, a pioneering computer program designed to autonomously create paintings. The terms generative AI planning or generative planning were used in the 1980s and 1990s to refer to AI planning systems, especially computer-aided process planning, used to generate sequences of actions to reach a specified goal. Generative AI planning systems used symbolic AI methods such as state space search and constraint satisfaction and were a "relatively mature" technology by the early 1990s. They were used to generate crisis action plans for military use, process plans for manufacturing and decision plans such as in prototype autonomous spacecraft.
Sources: en.wikipedia.org
The ending isotope of this chain is now known to be thallium-205. Some older sources give the final isotope as bismuth-209, but in 2003 it was discovered that it is very slightly radioactive, with a half-life of 2.01×1019 years. There are also non-transuranic decay chains of unstable isotopes of light elements, for example those of magnesium-28 and chlorine-39. On Earth, most of the starting isotopes of these chains before 1945 were generated by cosmic radiation. Since 1945, the testing and use of nuclear weapons has also released numerous radioactive fission products. Almost all such isotopes decay by either β− or β+ decay modes, changing from one element to another at the same atomic mass. The later daughter products in such a chain, being closer to beta-stability, generally have the longer half-lives.
Caitlin Thomas died in 1994 and was buried alongside her husband's grave. Thomas's father, "DJ", died on 16 December 1952 and his mother Florence in August 1958. Thomas's elder son, Llewelyn, died in 2000, his daughter, Aeronwy in 2009, and his younger son, Colm, in 2012.
== Public image == Kallingal's roles in 22 Female Kottayam, August Club, and Rani Padmini are cited among the strongest female-led characters in Malayalam cinema. Kallingal was named the Kochi Times Most Desirable Woman in 2012.
Some of the functions of tears include lubricating the eyes (basal tears), removing irritants (reflex tears), and also aiding the immune system. Tears also occur as a part of the body's natural pain response. Emotional secretion of tears may serve a biological function by excreting stress-inducing hormones built up through times of emotional distress. Tears have symbolic significance among humans.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.